Peripheral Cytokines as a Chemical Mediator for Postconcussion Like Sickness Behaviour in Trauma and Perioperative Patients: Literature Review

Yasir Rehman, Nadia Rehman, and Riaz Rehman

1 Neuro Science, Division of Neurology, Department of Medicine, Mc Master University, Hamilton, ON, Canada
2 CCRA, Mc Master University, Hamilton, ON, Canada
3 Gomal University, D I Khan, Pakistan
4 Windsor University, St Kits, Anguilla

Correspondence should be addressed to Yasir Rehman; dry_rehman@yahoo.ca

Received 6 November 2013; Revised 26 March 2014; Accepted 27 March 2014; Published 28 April 2014

1. Introduction

Neurocognitive and concussion like sickness behaviour is a cluster of signs and symptoms following a traumatic brain injury or systemic infections [1]. These signs and symptoms such as headaches, dizziness, neuropsychiatric manifestations, and cognitive impairment are usually deficits in somatic and behavioural domains [2]. Literature shows that impairment in mental functions following traumatic event has a common biological origin in the form of neuroinflammation [3], which triggers a complex cascade of events such as activation of inflammatory cells and proteins and expression of cytokines [1, 3]. These inflammatory events lead to unavoidable brain damage such as alteration in hippocampal cholinergic function, which mediate changes in cognition and behaviour [1]. The circumstantial data suggests that proinflammatory cytokines may play a role in instigating long-term cognitive and depressive like behaviour by infiltrating neurological tissue in individuals [4, 5].

Cytokines have been studied to assess neurologic injury in various surgeries, traumas, infections, strokes, neuropsychiatric disorders, and autoimmune diseases such as multiple sclerosis [6, 7]. Postoperative cognitive deficits such as impairment of recent memory, concentration, language comprehension, and social integration have been reported in 25.8% of patients one week after the surgery and in 9.9% of patients three months after the surgery [8]. Newman et al. in 2001 [9, 10] reported that neurocognitive decline (NCD) is a common complication with a prevalence up to 50%. The postoperative cognitive deficits also depend on type of surgery, medications, and preexisting medical conditions. The cognitive deficits after trauma and after operation are associated with significant decline in patient’s quality of life,
prolonged hospitalization, and increased overall morbidity and mortality [7].

In our opinion the overexpression of proinflammatory cytokines in muscular trauma directly influences the hippocampal dependent long-term potentiation and memory, that is, spatial memory, attention, executive function, object recognition, and contextual fear conditioning and synaptic plasticity. The higher cognitive processes rely heavily on learning and memory processes but their relationship with cytokines remains poorly understood. In this review we proposed cytokines and neuroinflammatory model of neurocognitive impairment in trauma situation. The main research question of the current study is whether there is an association of muscular IL-6, IL-1, TNF, and other inflammatory mediators with neurocognitive impairment when released as result of the trauma or perioperatively. Our main hypothesis is that IL-6, TNF, IL-1, and other inflammatory mediators released in muscular, orthopedic trauma or perioperative conditions are associated with neurocognitive impairment and concussion like illness and are not merely the result of anesthesia or medications. The purpose of this review is to systematically evaluate the literature and to clarify this entrenched belief. In our opinion, this hypothesis has implications for the pathogenesis and treatment of cognitive psychosomatic deficits in the trauma and postoperatively.

2. Evidence Acquisition and Synthesis

The McMaster University database using Ovid/MEDLINE database was searched for articles published between 1946 and July 2013 using the following combination of the terms: cognitive impairment, traumatic brain injury, cytokines (IL-1, IL-6, IL-8, and TNF-a), neuroinflammation, concussion like symptoms, blood brain barrier, systemic inflammatory response, and polytrauma. All articles were published in peer-reviewed journals, reporting original data on cytokines and systemic inflammatory response. All the key words were used by using mesh words and were initially combined by using “OR.” The words in each category such as neuroinflammation, cytokines, and cognition were then combined using “AND.” Our initial data search showed gave us 303447 in neurocognitive domains, 396588 in muscle and peripheral injury group, and 715522 in neuroinflammation category. On combing with "AND" the initial result was limited to 224 published articles. The selection was further limited to human and English language, which gave us 172 published articles. For articles review, I followed the PRISMA and “second chapter of 3rd edition of clinical epidemiology in clinical research.” We excluded all the review articles and animal study models. We also excluded articles that studied cytokines response in nontraumatic causes such as stroke, SAH, HIV, or infections, cancers, and immunotherapy. Out of those 172 published articles, 9 articles were selected to support the systemic effects of the cytokines, 23 articles to support the cognitive and behavioural symptoms that can be explained secondary to cytokines, and 21 articles to support the evidence that cytokines are related to peripheral trauma.

Summary of the Important Literature. Clinical studies of peripheral blood or autopsy specimens show elevated increases in cytokines TNF-α, IL-1β, and IL-6 in serum and cerebrospinal fluid (CSF) of patients with mild to moderate late-onset Alzheimer disease (AD) [11, 12]. Simultaneously, age-associated changes in glial reactivity may predispose individuals to exacerbated neuroinflammatory cytokine responses that are permissive to cognitive and behavioural complications [7].

Similar cognitive and behavioural symptoms are reported in perioperative process and trauma [7]. It has been suggested that surgical tissue trauma and stress response induce perioperative nonspecific inflammatory response. IL-6 response to injury is robust, being demonstrated across many types of injuries [13] including muscle, skin, bone, lung, and fat [14]. Elevated IL-6, in a lumbar decompression surgery, in the first 24 hours is associated with cognitive deficits and prolonged hospital stay [15]. Hogevoel et al. [16] reported that chemical mediators particularly IL-6, CK, TNF-alpha and IL-1 are strongly correlated with muscular injury response and surgery, which supports our opinion. Li et al. [17] found that only elevations in IL-6, S100b, were associated with cognitive impairment and delirium, following hip fracture surgery [17, 18]. Perioperative increase in CRP and inflammatory cytokines such as IL-1 and -10 is associated with neurocognitive deficits (NCD) in patients after cardiopulmonary bypass [6, 19]. Kálman et al. [20] reported elevated levels of inflammatory biomarkers in CSF as predictor of cognitive decline in coronary artery bypass surgery.

Haas [21] has found that professional amateur sports athletes, whiplash, and polytrauma patients show neurocognitive weakness in the absence of brain injuries, gram negative pathogenesis, infections, cerebrovascular disease, and neurodegeneration. Elevated serum IL-6 has been shown to correlate with multiorgan failure and death in polytrauma patients [22, 23]. Hensler et al. [24], Alexander [25], Gunstad and Suhr [26], and Iverson and Lange [27] reported increased serum concentrations of proinflammatory cytokines, including IL-6, in patients with multiple injuries and a high prevalence of the neurocognitive and behavioural symptoms (see Table 1).

In various diseases states, and behavioral syndromes, inflammatory biomarkers have been found to be positively correlated with fatigue [46–50, 61, 62], sleep disturbances and irritability [52–54, 63], and irritability [51]. Negative changes in mood and impaired learning and memory are significantly correlated with increases in IL-6, TNF-α, and IL-1 [17, 29].

On contrary to the above, there are studies that show that a decrease in peripheral systemic inflammation reduces the neuroinflammation, thus decreasing the sickness induction behaviour and improving cognitive functions. Acute and chronic exercises have anti-inflammatory effects, reducing levels of proinflammatory cytokines and CRP. Exercise as a therapy for PCS seems to be supported by the fact that young athletic individuals have evidence of anti-inflammatory mediators that oppose the actions of IL-6 and TNF-α [4]. Nonsteroidal anti-inflammatory drug (NSAIDs) user has a lower risk and progression of AD and NSAIDs are already being explored as a treatment for depression [64].
Table 1: The literature overview that studied cytokines release in condition other than TBI, infections, cardiac conditions, HIV, strokes, cerebrovascular conditions, cancers, immunotherapy, MS, or any condition in which the neurocognitive dysfunction is expected.

| Reference              | Systemic condition | Cytokines/inflammatory markers | PCS symptoms                               |
|------------------------|--------------------|--------------------------------|--------------------------------------------|
| Lenz et al. 2007 [22]  | Polytrauma, orthopedic trauma, polytrauma | IL-6                           | Cognitive impairment                       |
| Hergenroeder et al. 2010 [23] | Fracture surgery, postoperative hip replacement | IL-6, S-100 B                 | Cognitive impairment and delirium          |
| Hensler et al. 2002 [24] | Polytrauma          | IL-6                           | Systemic inflammatory response syndrome    |
| Li et al. 2012 [17]   | Fracture surgery    | IL-6, S-100 B                 | Cognitive impairment and delirium          |
| Dowlati et al. 2010 [28] | Meta-analysis, polytrauma | TNF-α and IL-6               | Depression                                 |
| Wright et al. 2005 [29] | Polytrauma          | IL-6, TNF-α, and IL-1         | Changes in mood, impaired learning and memory |
| Wilson et al. 2002 [12] | Physical stress    | IL-6                           | Physical or psychological stress           |
| Bastian et al. 2008 [30] | Trauma              | IL-1β, IL-6, TNF-α, and IFN-γ | Systemic inflammatory response syndrome    |
| Harrison et al. 2009 [138] | Trauma              | IL-6, IL-1, and TNF           | Changes in mood, impaired learning and memory |
| Haas 1996 [21]        | Professional amateur sports athletes | IL-6, IL-1, TNF               | PCS like symptoms and long-term depressive like behaviour |
| Kumbhare et al. 2009 [15] | Lumbar decompression surgery | IL-6                           | Cognitive impairment, systemic inflammatory response syndrome |
| Haensel et al. 2009 [31] | Obstructive sleep apnea | IL-6, TNF, TNF-R1             | Cognitive functioning, mood, and sleep     |
| Heffner et al. 2012 [32] | Acute stress       | IL-6                           | Cognitive tests, sleep quality, depressive symptoms, perceived stress, and loneliness |
| Tsaoussoglou et al. 2010 [33] | Excessive daytime sleepiness, inflammation, and metabolic abnormalities | (IL-6, TNF-alpha, CRP) | Sleep disruption, fatigability            |
| van de Vyver and Myburgh 2012 [34] | Biopsy              | IL-1, IL-6, IL-10, CK, TNF, LDH | Systemic inflammatory response syndrome, cognitive impairment |
| Smith 2000 [35]       | Overtraining syndrome (OTS) | IL-1-beta and/or IL-6 and/or TNF-alpha | Systemic inflammatory response syndrome |
| Perl et al. 2003 [14] | Blunt trauma        | IL-6, IL-8                     | Systemic inflammatory response syndrome    |
| Flohé et al. 2007 [36] | Soft tissue trauma, hip surgery | Heat shock protein, TNF-alpha | Systemic inflammatory response syndrome |
| Barr et al. 2004 [37] | Work-related musculoskeletal disorders | IL-1, CTGF                     | Decreased locomotor function               |
| Strecker et al. 2003 [38] | Blunt chest trauma | IL-8, IL-6, and CK            | Systemic inflammatory response syndrome    |

Acetylsalicylic acid has already been shown to accelerate remission in individuals who are not responsive to SSRIs [65]. Interestingly, a recent report from Tobinick and Gross shows a rapid cognitive improvement following perispinal etanercept (a potent TNF-α antagonist) administration in an Alzheimer patient [7].

3. Data from Preclinical or Animal Studies

Noninfectious systemic inflammatory markers have been independently associated with impaired cerebral blood flow [66]. Animal inflammatory models suggest focal dysregulation in cerebrovascular flow in areas important to
memory, such as the hippocampus [67]. Animals treated with cytokines, such as IL-1β or TNF-α or IFN-1β, exhibit "sickness behaviours," including reduced locomotor activity, diminished social interactions, and diminished consummatory behaviours [68]. Transgenic mice expressing IL-6 in glial cells show ataxia, seizures, and extensive neurodegeneration [69]. The animal model study shows differences in regional uptake such as the TNF uptake. TNF uptake into the hypothalamus is 9 times faster than into the parietal cortex and is not taken up by the striatum or the midbrain. Differences also exist between brain and spinal cord transport rates; for example, the transport rate of IL-1 into the spinal cord is about 80% of the brain. Variations also occurred among the regions of the spinal cord. The cervical spinal cord was the region with the fastest transport rate for both interferon (INF) and TNF [70]. Cauli et al. [71] reported that ibuprofen restored learning ability in rats with hepatic encephalopathy induced by portacaval shunts. The posttraumatic blood levels and pharmacological therapy aimed at enhancing the protective cytokines and inhibiting the damaging cytokines have shown improved survival rates in experimental animals [3].

4. Discussion

4.1. Peripheral Trauma-Cytokine-Neurocognitive and Behavioural Model. Trauma initiates immune reaction, circulating T Cells activation, proliferation, and cytokines expression [72]. Once activated, cytokines exert inflammatory and compensatory anti-inflammatory process and wound repair and healing mechanisms [73–75]. However their dysregulation and prolonged and excessive inflammatory response to pathophysiological insults lead to secondary injury, immune alteration, and multiorgan failure [76]. Release of cytokines also depends on the extent of the injury or trauma. A person is more prone to develop cognitive decline following a major muscular injury or surgery as compared to minor injury or laparoscopic surgery [77, 78].

After the major trauma or surgery, immune cells such as CD+4 T lymphocytes, peripheral blood mononuclear cells (PMBC), and macrophages are activated [79, 80]. Cytokines are derived from type I and II CD+4 helper T cells (HT). Type I CD+4 HT promote cytokines IL-1-alpha and -beta, IL-2, IFN-γ, and TNF. Type II CD+4 (HT) secrete cytokines such as IL-4, IL-6, and IL-10 [81]. A balance between the CD+4 (I and II) cells is critical to maintain immune homeostasis; however, imbalance between the two cell lineages is responsible for antigen presentation to peripheral blood mononuclear cells (PMBC), increase in expression of TNF, IL-1, and IL6, and alteration in antigen presentation and mitogen in trauma patients [78, 82, 83]. These systemic cytokines are involved in cell-to-cell communication and are partially propagated by systemic immune response system (SIRS) and multiorgan dysfunction (MODS) [22].

The brain is an immunologically active organ and is in direct communication with the immune and endocrine systems [12]. Human brain has IL-1, IL-2, IL-6, and TNF- cytokine receptors at frontal cortex, hippocampus, hypothalamus, cerebellums, and cerebrovascular endothelium [12]. The hippocampal formation and the dentate hilar region are differentially sensitive to injury relative to other regions of the brain, even in the absence of hypoxia or elevated intracranial pressure or without actual neuronal cell death [1].

Cytokines alert human brain through immunoneuropsychiatric (INP) cascade, secondary to peripheral inflammatory process due to injury [84]. In brain, the peripheral cytokines act as a second messenger and activate calcium, which triggers the blood brain barrier (BBB) damage and destruction of tight junctions [77, 85]. There are two mechanisms of cytokines transport across the blood brain barrier. First is direct or active transport of cytokines across the blood brain barrier through cytokines receptors. Second is indirect transport diffusion at the circumventricular region (CVO), where the BBB is incomplete [77]. CVO also prevents cytokines diffusing out. Another indirect mechanism of peripheral cytokines transport is via vagal nerve stimulation of nucleus tractus solitarius (NTS) in brain stem and then preoptic area of hypothalamus [12, 86, 87] (Figure 1).

Once in brain, the peripheral cytokines particularly IL-1 stimulate the microglia, which further stimulates the endogenous or central cytokines (IL-1, IL-6, and TNF-α production [77]). Once in the brain, both central and peripheral cytokines act through similar mechanism. Cytokines are pleotropic mediators and exert their effects through complex immune cascades, interaction with complement system, altered excitotoxic glutamate transmission, abnormal neurotransmission, oxidative stress, and nitric oxide production, leading to apoptotic neurodegeneration [88–90]. Neuroinflammation influences neuronal and axonal survival [91–95] and alters the central noradrenergic, dopaminergic, tryptophan, and serotoninergic neurotransmission in the hypothalamus hippocampus [96]. The cell debris and central stress further induce the central expression of IL-1, IL-6, and TNF in a vicious cycle [97, 98]. Cytokine known as mediator of physical and psychological stress also alters the hypothalamic-pituitary-adrenal axis and cortisol regulation [99]. Peripheral cytokines also exert indirect effects on the cognitions such as disrupting sleep regulation, micronutrient deficiency by appetite suppression, and endocrine interactions [70].

On the other hand, cognitive and behavioural stresses also influence cytokine production and alter the immunology equilibrium [100]. Thus central and peripheral cytokines mediated processes proceed in parallel to affect cognition. As a mediator of bidirectional communication between CNS and the peripheral immune system, systemic inflammatory reactions can influence brain function and conversely CNS processes may affect distant organs (Figures 2 and 3).

The most important and well-studied cytokines after peripheral trauma are IL-6, tumour necrosis factor-alpha (TNF-α), IL-1β, IL-2, IL-8, and IL-4 and recently IL-18, IL-12, and IFN-γ [15, 30]. In the periphery, IL-1, IL-6, and TNF are typically considered proinflammatory, whereas IL-4, IL-10, and IL-13 are typically considered anti-inflammatory [12]. The proinflammatory cytokines particularly IL-6 are the acute-phase response proteins that contribute to the development and resolution of signs and symptoms of acute and chronic inflammation after soft tissue injury [93, 101]; see Table 2.
Peripheral trauma/injury leads to MODS, which results in healed tissue and cytokines (IL-1, IL-6, and TNF) being released. These cytokines can then diffuse at the circumventricular region (through tight junction) and be transported actively via cytokine receptors. This leads to neurobehavioural manifestations.

Figure 1: Release and activation of peripheral cytokines from PMBC; mechanism of cytokines transport across the blood brain barrier; IL-1, IL-6, and TNF after crossing BBB stimulate microglia to secrete endogenous cytokines as well as affect neuronal cell/transmission directly. (PMBC—peripheral mononuclear blood cells, MODS—multiorgan dysfunction syndrome, TNF—tissue necrosis factor, IL-1—interleukin 1, and IL-6—interleukin 6).

Hypothalamus (preoptic area) interacts with the pituitary and the nucleus tractus solitarius (NTS) of the brain stem, releasing adrenal (cortisol) and activating the hypothalamus-pituitary-adrenal axis. Vagal nerve stimulation can also affect this axis.

Figure 2: Vagal nerve stimulation and effect on hypothalamus-pituitary-adrenal axis; peripheral cytokines after crossing the blood brain barrier (BBB) also directly affect hypothalamus-pituitary-adrenal axis.

**IL-1**. Peripheral IL-1 plays important role in neuroendocrine modulation, proliferation, and expression of microglia [3]. Peripheral IL-1 also alters central release and turnover of norepinephrine, serotonin, dopamine, and cholinergic neurotransmission [102]. IL-1 also affects hippocampal neurons and the synaptic plasticity [103–106], thus inhibiting the long-term potentiation (LTP) [107].

**IL-6**. Peripheral IL-6 is acute-phase protein, increases vascular permeability, and induces lymphocytic activation. IL-6 once in brain induces microglia and astrocyte activation, which further triggers the release of proinflammatory cytokines [108]. IL-6 alters the neuroendocrine neurotransmission, hypothalamic-pituitary-adrenal (HPA) axis, and ACTH release [109]. IL-6 alters the noradrenergic and serotonergic neurotransmission [109]. IL-6 impacts cognitive function via effects on synaptic plasticity [17, 110], decline in learning, memory, and long-term potentiation (LTP) [17].

**TNF-Alpha**. Tumor necrosis factor has neurodegenerative effects [111]. TNF has a direct effect on the LTP and synaptic plasticity [56]. It exerts its effects by activating caspases [112, 113], which activate the death signalling pathway [56] via glutamate excitation [56]. TNF alters the synaptic efficacy
### Table 2: The overview of common but important inflammatory markers involved in systemic inflammatory response and neurocognitive compromise.

| Inflammatory marker or cytokines (peripheral) | Reference | Associated conditions | Common symptom associated | Mechanism | Effect on other cytokines (if +) |
|---------------------------------------------|-----------|-----------------------|---------------------------|-----------|---------------------------------|
| IL-6                                        | Hergenroeder et al. 2010 [23] | Orthopedic, muscular injury, and surgery | Depression, memory impairment | HPA axis, alters NE, serotonin, dopamine, and cholinergic neurotransmission | Production of other cytokines and propagation of the inflammatory response |
| TNF-α                                       | Melanie Lancette-Hebert et al. 2007 [139] | Surgery, muscle injury, and depression, | LTP and synaptic scaling | Generation of free radicals such as NO, chronic hyperexcitability, and alterations in gene expression | Production of other cytokines and propagation of the inflammatory response |
| IL-1β                                       | Namas et al. 2009 [3] | Muscular injury, surgery | Inhibits the long term potentiation (LTP), synaptic plasticity | Proliferation of microglia, alteration of NE, serotonin, dopamine, and cholinergic neurotransmission | Synergistic action with other proinflammatory cytokines such as TNF-α |
| CRP                                         | Xie et al. 2009 [7] | Postoperative, muscular, and orthopedic injury, cardiac surgery | Memory and visuospatial impairment | Endothelial function, disruption of frontal subcortical pathways | IL-1, IL-6, TNF-a, IL-B, IL-10, and serum Tau protein |
| S-100 B                                     | Hayakata et al. 2004 [39] Sedaghat and Notopoulos 2008 [40] | Muscular injury | Cognitive dysfunction | Neurotoxic at higher concentration | IL-6, IL-8, IL-10, IL-1, and TNF-α |
| IL-2                                        | Anisman et al. 2002 [41] | Depressive state | Impaired spatial memory performance | Dopaminergic transmission, hippocampal LTP |  |
| INF                                         | Anisman et al. 2002 [41] | Depressive state | Cognitive dysfunction, confusion, and psychomotor slowing | Depletion of serotonin | IL-1, TNF |

by upregulating surface expression of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic (AMPA) receptors [114] and phosphatidylinositol 3 (PI3) kinase-dependent processes [115], thus causing a decrease in the synaptic inhibition and cognitive impairment [56].

CRP. CRP is the inflammatory marker and correlates with IL-6 secretion. CRP is associated with inflammation, impaired endothelial function, and cerebral amyloid deposits in areas important to memory, such as the hippocampus [116]. CRP is associated with memory, visuospatial impairment, and disruption of frontal subcortical pathways [117].

IL-2. IL-2 alters dopaminergic transmission and impairs the spatial memory performance via hippocampal neurodegeneration and suppression of long-term potentiation [118]. Immunotherapy, using IL-2, induces a depressive like state that may be attenuated by antidepressant treatment [41].

IFN-γ. IFN-gamma is associated with more general cognitive dysfunction, confusion, psychomotor slowing, parasthesia, visual disorientation anxiety, and depression [119]. IFN induces IL-1, TNF secretion, and depletion of serotonin, which contributes to cognitive and behavioural effects [120].

As previously mentioned, brain regions particularly dorsolateral frontal cortex, hippocampus, hypothalamus, cerebellums, and cerebrovascular endothelium are susceptible to cytokines and neuroinflammation. These brain regions are involved in memory, learning, executive functions, and personality. Therefore neuroinflammation in these regions leads to neurocognitive and behavioural changes. The manifestations of sickness behaviour include increased somatic complaints, lethargy, sleep disruption, reduced social activity, reduced mobility, anhedonia, decreased learning, anorexia, decreased libido, and neuropsychiatric side effects including depressed mood, poor motivation, and impaired thought processing [70]; see Table 3. Almost all the signs and
Table 3: The PCS symptoms explained based on the cytokines.

| PCS symptoms                      | Systemic illness                   | Reference                          | Cytokines associated                        |
|-----------------------------------|------------------------------------|------------------------------------|---------------------------------------------|
| Headache                          | Migraine headaches                 | Munno et al. 2001 [42]             | IL-10                                       |
|                                   | Review articles                    | Martelletti 2000 [43]              | IL-1B, TNF-α                                |
|                                   |                                    | Williamson and Hargreaves 2001 [44]| CGRP, calcitonin, and TNF-α                 |
| Fatigue                           | CARDIA                             | Cho et al. 2009 [45]               | CRP                                         |
|                                   | WBC                                | Raison et al. 2009 [46]            | CRP                                         |
|                                   | Cancer patients                    | Schubert et al. 2007 [47]          | CRP, IL-1, and IL-6                          |
|                                   | Coronary heart disease             | Janszky et al. 2005 [48]           | CRP, IL-1, and IL-6                          |
|                                   | Rheumatoid arthritis               | Davis et al. 2008 [49]             | CRP, IL-1, and IL-6                          |
|                                   | Multiple sclerosis                 | Heesen et al. 2006 [50]            | IFN-γ, TNF-α                                |
| Irritability                      | Verbal aggression and irritability  | Ahren-Moonga et al. 2008 [51]      | IL-6                                        |
| Insomnia or sleep disturbance     | Excessive daytime sleepiness,      | Vgontzas and Chrousos 2002 [52]    | IL-6 and/or TNF-α                           |
|                                   | sleep apnea, narcolepsy, and       |                                    |                                             |
|                                   | idiopathic hypersomnia             |                                    |                                             |
|                                   | Sleep deprivation                  | Vgontzas and Chrousos 2002 [52]    | IL-6, cortisol                              |
|                                   | Hemodialysis                       | Erten et al. 2005 [53],            | IL-B                                        |
|                                   |                                    | Chiu et al. 2009 [54]              |                                             |
| Reduced tolerance to stress,      | General stressors                  | Anisman et al. 2002 [41]           | IL-1β, TNF-α                                |
| emotional excitement              | Mood                               | Brydon et al. 2009 [55];           | IL-6, IL-1, and TNF-α                       |
|                                   |                                    | Himmelrich et al. 2006 [11]        |                                             |
| Cognitive and memory difficulties | Hippocampal dependent memory       | McAfoose and Baune 2009 [56]      | IL-1β, TNF-α                                |
|                                   | Cognitive functions                | McAfoose and Baune 2009 [56]      | IFN-γ (cognitive dysfunction), IL-6 (impaired learning and memory), and IL-2 (spatial working memory) |
| Anxiety, depression, personality  | ACS                                | Joska and Stein 2008 [57],         | IL-2, IFN-1B                                |
| changes, and apathy               | Immunotherapy                      | Poole et al. 2011 [19]             |                                             |
|                                   | Systemic trauma, depression        | Anisman et al. 2002 [41]           | IL-2, IFN-1B                                |
|                                   |                                    | Wright et al. 2005 [29],           |                                             |
|                                   |                                    | Reichenberg et al. 2001 [58],      |                                             |
|                                   |                                    | and Dowlati et al. 2010 [28]       |                                             |
|                                   | Systemic trauma                    | Meares et al. 2008 [4]             | IL-6, TNF-a                                 |
| Dizziness                         | Headaches, migraines               | Humphriss and Hall 2011 [59];     | IL-1B, TNF-a, and IL-10                     |
|                                   |                                    | Calhoun et al. 2011 [60]           |                                             |

Symptoms of disease, including altered behaviour and neuropsychiatric phenomena, can be accounted for by the actions of immune cell and peripheral cytokines secretions [93]. These profound discoveries have recently been applied to psychosocial disease, schizophrenia [35, 121], and depression [121, 122] yielding completely new models for the etiology of these unexplained diseases [123]. There is abundant evidence that peripheral inflammation can worsen or cause the axonal injury and exacerbate preexisting psychiatric disorders as well as the new onset of mood disorders (depression and mania), anxiety disorders, and psychotic disorders [1].

Overall, based on the above literature reviews, the peripheral inflammatory response interferes with cognitive function as evidenced by abnormal memory, learning, and inability to develop long-term potentiation in hippocampus [7]. Given that similar symptoms may be seen in such diverse situations as periovertially, after orthopedic or general trauma, perhaps it is time to consider PCS as merely one of many states in which there is an elevation of inflammatory cytokines. This hypothesis certainly opens a room to develop or determine inflammatory markers that might be helpful to address the cognitive weakness in postoperative and trauma patients and to study potential prediction of postsurgical or posttrauma risks and complications.

Currently, PCS or sickness behaviour such as neurocognitive and behavioural deficits is treated based on the specific symptoms primarily supportive to the individual [124] and as such not treating the underlying cause [11]. Despite ongoing research, little progress has been achieved in terms of prevention or management of this problem, largely because of an incomplete understanding of the pathophysiology of cognitive impairment, which is essential to improve outcomes.
In our opinion, some aggressive anti-inflammatory measures (including inflammatory cytokines antagonists or NSAIDs) may improve cognitive function in cognitive deficient subjects, particularly in trauma and perioperative patient. In our opinion the same will also be true for the PCS patients and may prevent the long-term neurologic sequelae of TBI, systemic inflammation, including cognitive impairment.

5. Conclusion

On the basis of the above overview, we believe there is sufficient clinical and research evidence to suggest clearly that cognitive impairment is not only limited to concussion, systemic infections and neurodegeneration. Furthermore, most PCS symptoms can be explained with current evidence by increased levels of cytokines such as IL-1β, IL-6, TNF-α, and IFN-γ, which are all important cytokines after trauma. Peripheral cytokines as those due to muscular injury or orthopedic trauma can influence neurotransmission and cause cognitive deficits. There is abundant evidence that there are cytokine-mediated interactions between neurons and glial cells, subserving cognition (e.g., cholinergic and dopaminergic pathways), and can modulate neuronal and glial cell function to facilitate neuronal regeneration and contribute to cognitive impairment.

Disclosure

The paper has not been published elsewhere and is not under simultaneous consideration by another journal.

Conflict of Interests

None of the authors has any conflict of interests to declare.

References

[1] J. M. Silver and T. W. McAllister, “Forensic issues in the neuropsychiatric evaluation of the patient with mild traumatic brain injury,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 9, no. 1, pp. 102–113, 1997.

[2] J. J. Bazarian, T. Wong, M. Harris, N. Leahey, S. Mookerjee, and M. Dombovy, “Epidemiology and predictors of post-concussive syndrome after minor head injury in an emergency population,” Brain Injury, vol. 13, no. 3, pp. 173–189, 1999.

[3] R. Namas, A. Ghuma, L. Hermus et al., “The acute inflammatory response in trauma/hemorrhage and traumatic brain injury: current state and emerging prospects,” Libyan Journal of Medicine, vol. 4, no. 3, pp. 97–103, 2009.

[4] S. Meares, A. E. Shores, A. J. Taylor et al., “Mild traumatic brain injury does not predict acute postconcussion syndrome,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 79, no. 3, pp. 300–306, 2008.

[5] T. Pollmächer, M. Haack, A. Schulz, A. Reichenberg, and R. Yirmiya, “Low levels of circulating inflammatory cytokines—do they affect human brain functions?” Brain, Behavior, and Immunity, vol. 16, no. 5, pp. 525–532, 2002.

[6] B. Ramlawi, J. L. Rudolph, S. Mieno et al., “C-Reactive protein and inflammatory response associated to neurocognitive decline following cardiac surgery,” Surgery, vol. 140, no. 2, pp. 221–226, 2006.

[7] G. Xie, W. Zhang, Y. Chang, and Q. Chu, “Relationship between perioperative inflammatory response and postoperative cognitive dysfunction in the elderly,” Medical Hypotheses, vol. 73, no. 3, pp. 402–403, 2009.

[8] J. T. Møller, P. Cluitmans, L. S. Rasmussen et al., “Long-term postoperative cognitive dysfunction in the elderly: ISPOCD1 study,” The Lancet, vol. 351, no. 9106, pp. 857–861, 1998.

[9] M. F. Newman, J. L. Kirchner, B. Phillips-Bute et al., “Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery,” The New England Journal of Medicine, vol. 344, no. 6, pp. 395–402, 2001.

[10] M. F. Newman, H. P. Grocott, J. P. Mathew et al., “Report of the substudy assessing the impact of neurocognitive function on quality of life 5 years after cardiac surgery,” Stroke, vol. 32, no. 12, pp. 2874–2881, 2001.

[11] M. Pollmächer, M. Haack, A. Schulz et al., “Elevated levels of inflammatory cytokines and chemokine upregulation by post-injury administration of a novel small molecule improves long-term neurologic outcome in a mouse model of traumatic brain injury,” Journal of Neuroinflammation, vol. 5, article 28, 2008.

[12] C. J. Wilson, C. E. Finch, and H. J. Cohen, “Cytokines and cognition—the case for a head-to-toe inflammatory paradigm,” Journal of the American Geriatrics Society, vol. 50, no. 12, pp. 2041–2056, 2002.

[13] D. S. Willoughby, B. McFarlin, and C. Bois, “Interleukin-6 expression after repeated bouts of eccentric exercise,” International Journal of Sports Medicine, vol. 24, no. 1, pp. 15–21, 2003.

[14] M. Perl, F. Gebhard, M. W. Knöferl et al., “The pattern of preformed cytokines in tissues frequently affected by blunt trauma,” Shock, vol. 19, no. 4, pp. 299–304, 2003.

[15] D. Kumbhare, W. Parkinson, B. Dunlop et al., “Injury measurement properties of serum interleukin-6 following lumbar decompression surgery,” Journal of Surgical Research, vol. 157, no. 2, pp. 161–167, 2009.

[16] H. E. Hogeved, T. Lyberg, K. Häkle, E. Haug, and O. Reikerås, “Changes in plasma IL-1β, TNF-α and IL-6 after total hip replacement surgery in general or regional anaesthesia,” Cytokine, vol. 12, no. 7, pp. 1156–1159, 2000.

[17] Y. C. Li, C. H. Xi, Y. F. An, W. H. Dong, and M. Zhou, “Perioperative inflammatory response and protein S-100 concentrations: Relationship with post-operative cognitive dysfunction in elderly patients,” Acta Anaesthesiologica Scandinavica, vol. 56, no. 5, pp. 595–600, 2012.

[18] B. C. van Munster, P. H. Bisschop, A. H. Zwinderman et al., “Cortisol, interleukins and S100B in delirium in the elderly,” Brain and Cognition, vol. 74, no. 1, pp. 18–23, 2010.

[19] L. Poole, C. Dickens, and A. Steptoe, “The puzzle of depression and acute coronary syndrome: reviewing the role of acute inflammation,” Journal of Psychosomatic Research, vol. 71, no. 2, pp. 61–68, 2011.

[20] J. Kalmán, A. Juhász, G. Bogáts et al., “Elevated levels of inflammatory biomarkers in the cerebrospinal fluid after coronary artery bypass surgery are predictors of cognitive decline,” Neurochemistry International, vol. 48, no. 3, pp. 177–180, 2006.

[21] C. D. Haas, “Chronic post-traumatic headaches classified and compared with natural headaches,” Cephalalgia, vol. 16, no. 7, pp. 486–493, 1996.

[22] A. Lenz, G. A. Franklin, and W. G. Cheadle, “Systemic inflammation after trauma,” Injury, vol. 38, no. 12, pp. 1336–1345, 2007.
[56] J. McAfoose and B. T. Baune, “Evidence for a cytokine model of cognitive function,” Neuroscience and Biobehavioral Reviews, vol. 33, no. 3, pp. 355–366, 2009.
[57] J. A. Joska and D. J. Stein, “Mood disorders,” in The American Psychiatric Publishing Textbook of Psychiatry, R. E. Hales, S. C. Yudofsky, and G. O. Gabbard, Eds., p. 457, American Psychiatric Publishing, Washington, DC, USA, 5th edition, 2008.
[58] A. Reichenberg, R. Yirmiya, A. Schuld et al., “Cytokine-associated emotional and cognitive disturbances in humans,” Archives of General Psychiatry, vol. 58, no. 5, pp. 445–452, 2001.
[59] R. L. Humphris and A. J. Hall, “Dizziness in 10 year old children: an epidemiological study,” International Journal of Pediatric Otorhinolaryngology, vol. 75, no. 3, pp. 395–400, 2011.
[60] A. H. Calhoun, S. Ford, A. P. Pruitt, and K. G. Fisher, “The point prevalence of dizziness or vertigo in migraine—and factors that influence presentation,” Headache, vol. 51, no. 9, pp. 1388–1392, 2011.
[61] R. J. Valentine, E. McAuley, V. J. Vieira et al., “Sex differences in the relationship between obesity, C-reactive protein, physical activity, depression, sleep quality and fatigue in older adults,” Brain, Behavior, and Immunity, vol. 23, no. 5, pp. 643–648, 2009.
[62] H. J. Cho, T. E. Seeman, J. E. Bower, C. I. Kiefe, and M. R. Irwin, “Prospective association between C-reactive protein and fatigue in the coronary artery risk development in young adults study,” Biological Psychiatry, vol. 66, no. 9, pp. 871–878, 2009.
[63] D. Riemann, C. Kloepfer, and M. Berger, “Functional and structural brain alterations in insomnia: implications for pathophysiology,” European Journal of Neuroscience, vol. 29, no. 9, pp. 1754–1760, 2009.
[64] F. Lowry, Antibiotics, Anti-Inflammatories Boost Depression Treatment, Medscape Medical News, 2011.
[65] J. Mendlewicz, P. Kriwi, P. Oswald, D. Soery, S. Alboni, and N. Brunello, “Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study,” International Clinical Psychopharmacology, vol. 21, no. 4, pp. 227–231, 2006.
[66] V. Novak, D. Last, D. C. Alsop et al., “Cerebral blood flow velocity and periventricular white matter hyperintensities in type 2 diabetes,” Diabetes Care, vol. 29, no. 7, pp. 1529–1534, 2006.
[67] A. Semmler, T. Okulla, M. Sastre, L. Dumitrescu-Ozimek, and M. T. Heneka, “Systemic inflammation induces apoptosis with variable vulnerability of different brain regions,” Journal of Chemical Neuroanatomy, vol. 30, no. 3-2, pp. 144–157, 2005.
[68] R. Dantzer, J. C. O’Connor, G. G. Freund, R. W. Johnson, and K. W. Kelley, “From inflammation to sickness and depression: when the immune system subjugates the brain,” Nature Reviews Neuroscience, vol. 9, no. 1, pp. 46–56, 2008.
[69] G. W. Hergenroeder, A. N. Moore, J. P. McCoy Jr. et al., “Serum IL-6: a candidate biomarker for intracranial pressure elevation following isolated traumatic brain injury,” Journal of Neuroinflammation, vol. 7, article 19, 2010.
[70] W. A. Banks, S. A. Farr, and J. E. Morley, “Entry of blood-borne cytokines into the central nervous system: effects on cognitive processes,” NeuroImmunoModulation, vol. 10, no. 6, pp. 319–327, 2002.
[71] O. Cauli, R. Rodrigo, B. Piedrafita, J. Boix, and V. Felipo, “Inflammation and hepatic encephalopathy: ibuprofen restores learning ability in rats with portacaval shunts,” Hepatology, vol. 46, no. 2, pp. 514–519, 2007.
[72] V. A. Lennon, “Cross-talk between nervous and immune systems in response to injury,” Progress in Brain Research, vol. 103, pp. 289–292, 1994.
[73] P. Meade, W. C. Shoemaker, T. J. Donnelly et al., “Temporal patterns of hemodynamics, oxygen transport, cytokine activity, and complement activity in the development of adult respiratory distress syndrome after severe injury,” Journal of Trauma, vol. 36, no. 5, pp. 651–657, 1994.
[74] W. L. Biff, E. E. Moore, F. A. Moore, and V. M. Peterson, “Interleukin-6 in the injured patient: marker of injury or mediator of inflammation?” Annals of Surgery, vol. 224, no. 5, pp. 647–664, 1996.
[75] Z. Kronfol and D. G. Remick, “Cytokines and the brain: implications for clinical psychiatry,” The American Journal of Psychiatry, vol. 157, no. 5, pp. 683–694, 2000.
[76] B. H. Harris and J. A. Gelfand, “The immune response to trauma,” Seminars in Pediatric Surgery, vol. 4, no. 2, pp. 77–82, 1995.
[77] A. Yarlagadda, E. Alfonso, and A. H. Clayton, “The blood brain barrier and the role of cytokines in neuropsychiatry,” Psychiatry, vol. 6, no. 11, pp. 18–22, 2009.
[78] L. M. Shahbazian, M. Jeevanandam, and S. R. Petersen, “Release of proinflammatory cytokines by mitogen-stimulated peripheral blood mononuclear cells from critically ill multiple-trauma victims,” Metabolism: Clinical and Experimental, vol. 48, no. 11, pp. 1397–1401, 1999.
[79] S. Kurosawa and M. Kato, “Anesthetics, immune cells, and immune responses,” Journal of Anesthesia, vol. 22, no. 3, pp. 263–277, 2008.
[80] N. N. Choileain and H. P. Redmond, “Cell response to surgery,” Archives of Surgery, vol. 141, no. 11, pp. 1132–1140, 2006.
[81] E. Faist, C. Schinkel, and S. Zimmer, “Update on the mechanisms of immune suppression of injury and immune modulation,” World Journal of Surgery, vol. 20, no. 4, pp. 454–459, 1996.
[82] N. N. Choileain and H. P. Redmond, “Cell response to surgery,” Archives of Surgery, vol. 141, no. 11, pp. 1132–1140, 2006.
[83] S. Kurosawa and M. Kato, “Anesthetics, immune cells, and immune responses,” Journal of Anesthesia, vol. 22, no. 3, pp. 263–277, 2008.
[84] D. Adams, M. Lunn, F. C. Martin et al., “Cytokines and IGF-I in delirious and non-delirious acutely ill older medical inpatients,” Age and Ageing, vol. 38, no. 3, pp. 326–332, 2009.
[85] W. Pan, S. Xiang, H. Tu, and A. Kastin, “Cytokines interact with the blood-brain-barrier,” in Blood-Brain Interface: From Ontogeny to Artificial Barriers, R. Dermietzel, D. Spray, and M. Nedergaard, Eds., pp. 247–258, Wiley-VCH, Weinheim, Germany, 2006.
[86] L. E. Goehler, R. P. A. Gaykema, K. T. Nguyen et al., “Interleukin-1β in immune cells of the abdominal vagus nerve: a link between the immune and nervous systems?” Journal of Neuroscience, vol. 19, no. 7, pp. 2799–2806, 1999.
[87] S. F. Maier, L. E. Goehler, M. Fleshner, and L. R. Watkins, “The role of the vagus nerve in cytokine-to-brain communication,” in Cytokines and the Brain: Inflammation to Immune Modulation, R. Dermietzel, D. Spray, and M. Nedergaard, Eds., pp. 261–278, Springer, Germany, 2002.
[88] A. J. Bruce-Keller, “Microglial-neuronal interactions in synaptic damage and recovery,” Journal of Neuroscience Research, vol. 58, pp. 191–201, 1999.
[89] R. Veerhuis, I. Janssen, C. J. A. de Groot, F. L. van Muiswinkel, C. E. Hack, and P. Eikelenboom, “Cytokines associated with amyloid plaques in Alzheimer’s disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor,” Experimental Neurology, vol. 160, no. 1, pp. 289–299, 1999.
A. J. Cunningham, C. A. Murray, L. A. J. O’Neill, M. A. Lynch, Y. Li, L. Liu, J. Kang et al., “Neuronal-glial interactions mediate the neuroprotection in hippocampus in vivo,” *Neuroscience Letters*, vol. 203, no. 1, pp. 17–20, 1996.

H. Katsuki, S. Nakai, Y. Hirai, K. Akaji, Y. Kiso, and M. Satoh, “Interleukin-1β inhibits long-term potentiation in the CA3 region of mouse hippocampal slices,” *European Journal of Pharmacology*, vol. 181, no. 3, pp. 323–326, 1990.

C. A. Murray and M. A. Lynch, “Evidence that increased hippocampal expression of the cytokine interleukin-1β is a common trigger for age- and stress-induced impairments in long-term potentiation,” *Journal of Neuroscience*, vol. 18, no. 8, pp. 2974–2981, 1998.

A. N. Coogan, L. A. J. O’Neill, and J. J. O’Connor, “The P38 mitogen-activated protein kinase inhibitor SB203580 antagonizes the inhibitory effects of interleukin-1β on long-term potentiation in the rat dentate gyrus in vitro,” *Neuroscience*, vol. 93, no. 1, pp. 57–69, 1999.

E. N. Benveniste, “Cytokine actions in the central nervous system,” *Cytokine and Growth Factor Reviews*, vol. 9, no. 3-4, pp. 259–275, 1998.

C. Song, Z. Merali, and H. Anisman, “Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment,” *Neuroscience*, vol. 88, no. 3, pp. 823–836, 1999.

M. L. Monje, H. Toda, and T. D. Palmer, “Inflammatory blockade restores adult hippocampal neurogenesis,” *Science*, vol. 302, no. 5651, pp. 1760–1765, 2003.

R. T. Perry, J. S. Collins, H. Wiener, R. Acton, and R. C. P. Go, “The role of TNF and its receptors in Alzheimer’s disease,” *Neurobiology of Aging*, vol. 22, no. 6, pp. 873–883, 2001.

D. J. MacEwan, “TNF ligands and receptors—a matter of life and death,” *The British Journal of Pharmacology*, vol. 135, no. 4, pp. 855–875, 2002.

D. J. MacEwan, “TNF receptor subtype signalling: differences and cellular consequences,” *Cellular Signalling*, vol. 14, no. 6, pp. 477–492, 2002.

E. C. Beattie, D. Stellwagen, W. Morishita et al., “Control of synaptic strength by glial TNFα,” *Science*, vol. 295, no. 5563, pp. 2282–2285, 2002.

D. Stellwagen, E. C. Beattie, J. Y. SEO, and R. C. Malenka, “Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-α,” *Journal of Neuroscience*, vol. 25, no. 12, pp. 3219–3228, 2005.

A. Semmler, T. Okulla, M. Sastre, L. Dumitrescu-Ozimek, and M. T. Heneka, “Systemic inflammation induces apoptosis with variable vulnerability of different brain regions,” *Journal of Chemical Neuroanatomy*, vol. 30, no. 2-3, pp. 144–157, 2005.

K. P. Guggenheim and L. A. Lipsitz, “The microvascular frontotemporal subcortical syndrome of aging,” *Neurobiology of Aging*, vol. 23, no. 3, pp. 421–431, 2002.

H. J. Park, C. K. Won, K. H. Pyun, and H. Shin, “Interleukin 2 suppresses afferent sensory transmission in the primary somatosensory cortex,” *NeuroReport*, vol. 6, no. 7, pp. 1018–1020, 1995.

Y. X. Wang, C. L. Jiang, C. L. Lu et al., “Distinct domains of IFNα mediate immune and analgesic effects respectively,” *Journal of Neuroimmunology*, vol. 108, no. 1, pp. 64–67, 2000.

A. D. Valentine, C. A. Meyers, M. A. Kling, E. Richelson, and P. Hauser, “Mood and cognitive side effects of interferon-α therapy,” *Seminars in Oncology*, vol. 25, no. 1, pp. 39–47, 1998.
[121] R. S. Smith, “The macrophage theory of depression,” Medical Hypotheses, vol. 35, no. 4, pp. 298–306, 1991.

[122] R. S. Smith, “The immune system is a key factor in the etiology of psychosocial disease,” Medical Hypotheses, vol. 34, no. 1, pp. 49–57, 1991.

[123] R. S. Smith, “The cytokine theory of headache,” Medical Hypotheses, vol. 39, no. 2, pp. 168–174, 1992.

[124] T. W. McAllister and D. Arciniegas, “Evaluation and treatment of postconcussive symptoms,” NeuroRehabilitation, vol. 17, no. 4, pp. 265–283, 2002.